These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26212113)

  • 1. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
    Yu M; Lee C; Wang M; Tannock IF
    Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors.
    Patel KJ; Lee C; Tan Q; Tannock IF
    Clin Cancer Res; 2013 Dec; 19(24):6766-76. PubMed ID: 24141627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
    Azzarito T; Venturi G; Cesolini A; Fais S
    Cancer Lett; 2015 Jan; 356(2 Pt B):697-703. PubMed ID: 25449440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration.
    Lee CM; Tannock IF
    Br J Cancer; 2006 Mar; 94(6):863-9. PubMed ID: 16495919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion.
    Zhang S; Wang Y; Li SJ
    Biochem Biophys Res Commun; 2014 Jun; 448(4):424-9. PubMed ID: 24802401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Wang CJ; Li D; Danielson JA; Zhang EH; Dong Z; Miller KD; Li L; Zhang JT; Liu JY
    Cancer Lett; 2021 Jul; 509():1-12. PubMed ID: 33813001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.
    Primeau AJ; Rendon A; Hedley D; Lilge L; Tannock IF
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8782-8. PubMed ID: 16361566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
    Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
    Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
    Canitano A; Iessi E; Spugnini EP; Federici C; Fais S
    Cancer Lett; 2016 Jul; 376(2):278-83. PubMed ID: 27084522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES; Na K; Bae YH
    J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
    Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
    Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
    Patel KJ; Trédan O; Tannock IF
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump.
    Fan S; Niu Y; Tan N; Wu Z; Wang Y; You H; Ke R; Song J; Shen Q; Wang W; Yao G; Shu H; Lin H; Yao M; Zhang Z; Gu J; Qin W
    Oncogene; 2013 Mar; 32(13):1682-90. PubMed ID: 22580606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitors may reduce tumour resistance.
    De Milito A; Fais S
    Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-homing, pH- and ultrasound-responsive polypeptide-doxorubicin nanoconjugates overcome doxorubicin resistance in cancer therapy.
    Wang Z; He Q; Zhao W; Luo J; Gao W
    J Control Release; 2017 Oct; 264():66-75. PubMed ID: 28837822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of β-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice.
    Hanušová V; Caltová K; Svobodová H; Ambrož M; Skarka A; Murínová N; Králová V; Tomšík P; Skálová L
    Biomed Pharmacother; 2017 Nov; 95():828-836. PubMed ID: 28903178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).
    Zinonos I; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Anticancer Res; 2014 Dec; 34(12):7007-20. PubMed ID: 25503127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.